September 9th, 2014
Podcast 174: PARADIGM and Heart Failure
The PARADIGM-HF trial of LCZ696 — a novel compound that both blocks the renin-angiotensin system with an ARB component and blocks neprilysin’s degradation of natriuretic peptides — increased survival in heart failure by some 20% relative to enalapril. It seems to be a big deal, and the trial’s two principal authors have agreed to talk […]
About the Podcast
Comments, suggestions, and story ideas welcome. Learn more about Clinical Conversations.
Follow us:
